IGF-1 is a useful measurement with a specific purpose
IGF-1 stands for insulin-like growth factor 1. It is a hormone involved in the effects of growth hormone. Growth hormone fluctuates during the day, while IGF-1 is more stable, making it useful when clinicians evaluate or monitor growth-hormone disorders. Levels also change with age. [1]
For someone considering sermorelin, the important question is why the test is being ordered and what decision the result could change. Ask that before treating a number as a score to maximize. Keep the full report, its reference interval and the clinician’s interpretation together. A screenshot of a single value removes much of the context needed for a useful discussion.
A biomarker is not automatically a treatment benefit
FDA distinguishes biomarkers—measured indicators of a biological state or response—from clinical outcomes, such as how a person feels or functions. A surrogate endpoint stands in for a clinical outcome only when the evidence supports using it in that context. [2]
Applied to a sermorelin advertisement, our reading is straightforward: an increase in IGF-1 does not, by itself, establish improved sleep, strength, recovery or lifespan. Those are separate claims that need appropriate outcome evidence. This is not an argument that laboratory testing is unhelpful. It is a reason to be precise about what the result does and does not answer.
Use the same distinction when reading a study or customer survey. A hormone graph, a questionnaire and a physical-performance test are different measurements. They can inform one another, but they should not be substituted silently in a headline.
A real trial shows why the distinction matters
In a placebo-controlled study of MK-677, a different drug from sermorelin, researchers observed increases in growth hormone and IGF-1 alongside increased fat-free mass, but no improvement in strength or function. The original randomized trial.[3] This example illustrates a measurement problem; it is not evidence that sermorelin has the same effects or risks.
When you see a study cited, trace the claim through three steps: the ingredient researchers used, the measurement that changed, and the real-world outcome the advertisement implies. If the last step was not measured, it remains a question. Our sermorelin and MK-677 comparison separates those ingredients and the limits of their evidence.
A low result is not a prescription decision on its own
MedlinePlus notes that a low IGF-1 result may reflect a normal age-related decrease or other conditions. Further testing may be needed when a growth-hormone disorder is suspected. How IGF-1 results are interpreted.[1] Avoid using an online target range to diagnose yourself or adjust medication.
Ask the ordering clinician whether the result is meaningful for your age and medical circumstances, whether it should be repeated, and whether another explanation needs attention. If two reports seem inconsistent, bring both complete reports. The clinical interpretation matters more than whether a marketing chart labels your result “optimal.”
Decide what follow-up should answer
Before a recurring plan begins, ask which laboratory and day-to-day outcomes will be reviewed, when review will occur and what would lead to a change. Make room for an inconclusive result: a laboratory change and how you feel may point in different directions. A good follow-up conversation should address that uncertainty.
Keep the monitoring plan separate from the billing calendar. Confirm who orders any tests, who explains them and whether they cost extra. Add those items to the consultation checklist and your cost estimate. Neither this guide nor a provider comparison can set an individual IGF-1 target or replace interpretation by your own clinician.